Clinically relevant fluorouracil + leucovorin interactions in patients with colorectal cancer;Klinisch relevante interacties van fluorouracil + leucovorine bij patiënten met colorectale kanker

Pharmaceutisch Weekblad

Volumn 139, Issue 42, 2004, Pages 1392-1396

  Jansman, F G A ^a   Jansen, J A ^b   Coenen, J L L M ^a   De Graaf, J C ^a   Smit, W M ^c   Brouwers, J R B J ^d  

^a ISALA HOSPITAL   (Netherlands)

^b Rijksuniversiteit Croningen   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALPHA INTERFERON; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CIMETIDINE; DIPYRIDAMOLE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; LEVAMISOLE; METRONIDAZOLE; PHENYTOIN; PYRIDOXINE; SORIVUDINE; TAMOXIFEN; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONJUNCTIVITIS; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG POTENTIATION; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HAND FOOT AND MOUTH DISEASE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 6344276665     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol. 2000;18:1780-99.
2. Corcoran ME. Polypharmacy in the older patient with cancer. Cancer Control. 1997;4:419-28.
3. Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48:133-43.
4. Van Roon EN, Kerremans A, Flikweert S, et al. Van 0A to 4F. Gestructureerde beoordeling van geneesmiddeleninteracties. Pharm Weekbl. 2002;137:255-60.
5. Van Roon EN, Langendijk PNJ, Flikweert S, et al. Wikken en wegen. Gestructureerde beoordeling van geneesmiddelinteracties. Pharm Weekbl. 2003;138:850-5.
6. Guidelines for ATC classification and DDD assignement. Oslo: WHO Collaborating Centre for Drug Statistics. http://www.whocc.no.
7. International Common Toxicity Criteria, version 2.0. National Cancer Institute. http://ctep.info.nih.gov/CTC3default.htm.
8. Sjoqvist F. FASS 2000. Stockholm: LINFO Drug Information; 2000:1481-6.
9. Stockley IH. Drug interactions 5 de ed. Oxford: Blackwell Science; 1999.
10. Hansten PD, Horn JR. Drug interactions. Missouri: Facts and Comparisons; 2001.
11. Note for guidance on the investigation of drug interactions. Londen: EMEA/CPMP; 1997.
12. Illiger HJ, Bornmann L, Herdrich K. Drug interactions in the therapy of malignant diseases. ASTA Medica Oncology, 2001.
13. Drugdex Drug Evaluations. Fluorouracil. Update 22 april 2003.
14. Fluouracil[1B-tekst]. Haarlem: Teva; 2003.
15. De Smet PAG, Brouwers JRBJ. Pharmacokinetic evaluation of herbal remedies: basic introduction, applicability, current status and regulatory needs. Clin Pharmacokinet. 1997;32:427-36.
16. Poon MA, O'Connell MJ, Moertel CC, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989;7:1407-17.
17. Laufman LR, Krzeczowski KA, Roach R, et al. Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colon cancer. J Clin Oncol. 1987;5:1394-400.
18. Jansman FCA, Coenen JLLM, De Craaf JC, et al. Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid. Anticancer Res. 2002;22:3449-56.
19. Jansman FGA, Sleijfer DT, De Craaf JC, et al. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf. 2001;24:353-67.
20. Grogan L, Sotos CA, Allegra CJ. Leucovorin modulation of fluorouracil. Oncology. 1993:7:63-72.